Predictors of switching antipsychotic medications in the treatment of schizophrenia
To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychoti...
Saved in:
Published in | BMC psychiatry Vol. 10; no. 1; p. 75 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
28.09.2010
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia.
This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication.
About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy.
Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics. |
---|---|
AbstractList | To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia.BACKGROUNDTo identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia.This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication.METHODSThis post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication.About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy.RESULTSAbout one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy.Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics.CONCLUSIONSSwitching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics. Abstract Background To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. Methods This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication. Results About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy. Conclusions Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics. To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication. About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy. Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics. To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication. About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy. Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics. Background To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the long-term treatment of schizophrenia. Methods This post-hoc analysis used data from a one-year randomized, open-label, multisite study of antipsychotics in the treatment of schizophrenia. The study protocol permitted switching of antipsychotics when clinically warranted after the first eight weeks. Baseline patient characteristics were assessed using standard psychiatric measures and reviews of medical records. The prediction model included baseline sociodemographics, comorbid psychiatric and non-psychiatric conditions, body weight, clinical and functional variables, as well as change scores on standard efficacy and tolerability measures during the first two weeks of treatment. Cox proportional hazards modeling was used to identify the best predictors of switching from the initially assigned antipsychotic medication. Results About one-third of patients (29.5%, 191/648) switched antipsychotics before the end of the one-year study. There were six variables identified as the best predictors of switching: lack of antipsychotic use in the prior year, pre-existing depression, female gender, lack of substance use disorder, worsening of akathisia (as measured by the Barnes Akathisia Scale), and worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of antipsychotic therapy. Conclusions Switching antipsychotics appears to be prevalent in the naturalistic treatment of schizophrenia and can be predicted by a small and distinct set of variables. Interestingly, worsening of anxiety and depressive symptoms and of akathisia following two weeks of treatment were among the more robust predictors of subsequent switching of antipsychotics. |
ArticleNumber | 75 |
Audience | Academic |
Author | Ascher-Svanum, Haya Nyhuis, Allen W Stauffer, Virginia L Faries, Douglas E Kinon, Bruce J |
AuthorAffiliation | 1 Eli Lilly and Company, Indianapolis, IN USA |
AuthorAffiliation_xml | – name: 1 Eli Lilly and Company, Indianapolis, IN USA |
Author_xml | – sequence: 1 givenname: Allen W surname: Nyhuis fullname: Nyhuis, Allen W – sequence: 2 givenname: Douglas E surname: Faries fullname: Faries, Douglas E – sequence: 3 givenname: Haya surname: Ascher-Svanum fullname: Ascher-Svanum, Haya – sequence: 4 givenname: Virginia L surname: Stauffer fullname: Stauffer, Virginia L – sequence: 5 givenname: Bruce J surname: Kinon fullname: Kinon, Bruce J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20920179$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUl1rFDEUHaRiP_TZNxn0wadpk8nk60Voix-FgoIKvoVM5mY3y2yyJlml_nozu3XplhbJw2Ruzjmce-49rg588FBVLzE6xViwM9xx3LRd96PBqOH0SXW0qxzcuR9WxyktEMJcUPysOmyRbMuPPKq-fokwOJNDTHWwdfrtspk7P6u1z26Vbsw8ZGfq5QTS2QWfaufrPIc6R9B5CT5veIX0J6zmEbzTz6unVo8JXtx-T6rvH95_u_zUXH_-eHV5ft30rCO5YYYTYBwRoHbAbWcxIDJAjzttoUeIAQPSa8Kt4Mj0RHBgeEAIQA9ADCYn1dVWdwh6oVbRLXW8UUE7tSmEOFM6FvcjKA3MWsEQsUZ0gvVaciF1LxmScuC2K1rvtlqrdV-aNaWvqMc90f0X7-ZqFn6pVlLKyGTmYivQu_CIwP6LCUs1DUhNA1IYKU6LyNtbFzH8XEPKaumSgXHUHsI6KUk7KnFL8X-RnApBCKGoIF_fQy7COvoyGCVRiwXv6NT-my1opktazttQPJpJUp23RLZSMNkW1OkDqHIGWDpTNtO6Ut8jvLqb6i6Nf_tXAGdbgIkhpQh2BymBTBv-QET0HsO4vNnM4sWNj_L-AlIh_6M |
CitedBy_id | crossref_primary_10_1155_2011_317368 crossref_primary_10_1517_14656566_2014_884071 crossref_primary_10_1177_1039856218810166 crossref_primary_10_1186_1471_244X_13_248 crossref_primary_10_1016_j_schres_2020_12_006 crossref_primary_10_18553_jmcp_2024_23319 crossref_primary_10_1016_j_heliyon_2024_e39792 crossref_primary_10_1097_YIC_0000000000000296 crossref_primary_10_1177_2045125312453935 crossref_primary_10_1186_1471_244X_13_221 crossref_primary_10_1016_j_schres_2015_10_040 crossref_primary_10_1097_YIC_0000000000000372 crossref_primary_10_1016_j_psychres_2013_07_030 crossref_primary_10_1089_cap_2010_0095 crossref_primary_10_16946_kjsr_2017_20_2_69 crossref_primary_10_1016_S2215_0366_23_00262_6 crossref_primary_10_1016_j_rpsmen_2011_07_001 crossref_primary_10_1111_papt_12265 crossref_primary_10_1186_s12991_023_00472_z crossref_primary_10_2147_NDT_S358392 crossref_primary_10_1007_s40263_015_0282_7 crossref_primary_10_2190_PM_45_2_c crossref_primary_10_3390_ijerph20054376 crossref_primary_10_1016_j_encep_2017_02_007 crossref_primary_10_1016_j_schres_2021_11_020 crossref_primary_10_1177_0269881112463469 crossref_primary_10_1017_S1092852918001086 crossref_primary_10_1186_1744_859X_12_1 crossref_primary_10_1097_YIC_0000000000000068 crossref_primary_10_1186_1471_244X_14_53 crossref_primary_10_1186_s12888_016_0879_5 crossref_primary_10_1177_0706743717718166 crossref_primary_10_3390_jcm11195965 crossref_primary_10_17826_cumj_903054 crossref_primary_10_1016_j_rpsm_2011_07_003 |
Cites_doi | 10.1093/schbul/sbm134 10.1016/S0920-9964(01)00326-7 10.1111/j.1524-4733.2006.00083.x 10.1176/appi.ajp.160.11.2063 10.1176/appi.ajp.159.9.1534 10.1176/ajp.2006.163.4.611 10.4088/JCP.v68n0301 10.1192/bjp.154.5.672 10.1093/schbul/13.2.261 10.1186/1471-244X-6-8 10.1192/bjp.184.4.346 10.1176/appi.ps.52.6.805 10.1185/030079907X162665 10.1192/bjp.191.50.s64 10.1093/schbul/21.3.419 10.1176/ajp.142.4.499 10.1001/archpsyc.59.10.877 10.1186/1471-244X-9-54 10.1001/jama.290.12.1624 10.1177/0269881105058978 10.4088/JCP.v64n0514 10.1056/NEJMoa051688 10.1186/1741-7015-3-21 10.1097/01.jcp.0000245562.99036.92 10.4088/JCP.v65n0812 10.1001/archpsyc.1976.01770060086012 10.1093/schbul/sbm161 10.1111/j.1600-0447.1970.tb02066.x 10.4088/JCP.v67n0317 10.1176/appi.ps.54.10.1407 10.1176/ajp.2007.164.3.415 10.1016/j.biopsych.2005.02.023 10.1097/JCP.0b013e318185e74a 10.1016/0149-7189(88)90033-X 10.1097/00005650-199206000-00002 10.1176/ajp.2006.163.4.600 10.4088/JCP.v67n0715 10.1002/hup.325 10.1097/00004714-200206000-00003 10.2466/pr0.1962.10.3.799 10.1007/BF02287330 10.1136/bmj.321.7273.1360 10.4088/JCP.v62n1003 10.1192/bjp.187.2.137 10.1001/archpsyc.60.12.1228 10.1177/0269881105056668 10.1016/j.schres.2009.04.018 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2010 BioMed Central Ltd. 2010 Nyhuis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2010 Nyhuis et al; licensee BioMed Central Ltd. 2010 Nyhuis et al; licensee BioMed Central Ltd. |
Copyright_xml | – notice: COPYRIGHT 2010 BioMed Central Ltd. – notice: 2010 Nyhuis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2010 Nyhuis et al; licensee BioMed Central Ltd. 2010 Nyhuis et al; licensee BioMed Central Ltd. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 88G 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. M0S M1P M2M PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM DOA |
DOI | 10.1186/1471-244X-10-75 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database Psychology Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database Neurosciences Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-244X |
EndPage | 75 |
ExternalDocumentID | oai_doaj_org_article_ae6ff8603fc8486ba9789ab96099d7f4 PMC2955631 oai_biomedcentral_com_1471_244X_10_75 2502954941 A239298692 20920179 10_1186_1471_244X_10_75 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GroupedDBID | --- 0R~ 23N 2VQ 2WC 4.4 53G 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C1A C6C CCPQU CITATION CS3 DIK DWQXO E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GNUQQ GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ IPY ITC KQ8 M1P M2M M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PSYQQ RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7TK 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 ABVAZ AFGXO AFNRJ 5PM PUEGO |
ID | FETCH-LOGICAL-b643t-6c73e6703e5fd124f1e03deb14afeb006e6e3ba37f870cb387e61d00eeade3c13 |
IEDL.DBID | RBZ |
ISSN | 1471-244X |
IngestDate | Wed Aug 27 00:32:06 EDT 2025 Thu Aug 21 18:13:01 EDT 2025 Wed May 22 07:10:24 EDT 2024 Fri Jul 11 03:53:33 EDT 2025 Fri Jul 11 09:02:46 EDT 2025 Fri Jul 25 04:28:19 EDT 2025 Tue Jun 17 21:19:16 EDT 2025 Tue Jun 10 20:13:47 EDT 2025 Thu Jan 02 22:06:26 EST 2025 Thu Apr 24 22:57:31 EDT 2025 Tue Jul 01 01:46:14 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b643t-6c73e6703e5fd124f1e03deb14afeb006e6e3ba37f870cb387e61d00eeade3c13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | http://dx.doi.org/10.1186/1471-244X-10-75 |
PMID | 20920179 |
PQID | 902187454 |
PQPubID | 44775 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ae6ff8603fc8486ba9789ab96099d7f4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2955631 biomedcentral_primary_oai_biomedcentral_com_1471_244X_10_75 proquest_miscellaneous_954591251 proquest_miscellaneous_758833350 proquest_journals_902187454 gale_infotracmisc_A239298692 gale_infotracacademiconefile_A239298692 pubmed_primary_20920179 crossref_primary_10_1186_1471_244X_10_75 crossref_citationtrail_10_1186_1471_244X_10_75 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-09-28 |
PublicationDateYYYYMMDD | 2010-09-28 |
PublicationDate_xml | – month: 09 year: 2010 text: 2010-09-28 day: 28 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC psychiatry |
PublicationTitleAlternate | BMC Psychiatry |
PublicationYear | 2010 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | J Endicott (705_CR29) 1976; 33 MJ Sernyak (705_CR12) 2005; 32 TS Stroup (705_CR7) 2007; 164 JP McEvoy (705_CR4) 2006; 163 TS Stroup (705_CR6) 2006; 163 O Agid (705_CR20) 2003; 60 H Ascher-Svanum (705_CR48) 2006; 6 WW Fleischhacker (705_CR45) 1994; 382 HY Meltzer (705_CR50) 2003; 59 LA Lindamer (705_CR37) 2003; 54 HC Kraemer (705_CR32) 2002; 59 PJ Weiden (705_CR35) 1995; 21 JE Overall (705_CR19) 1962; 10 H Ascher-Svanum (705_CR39) 2006; 67 BL Svarstad (705_CR38) 2001; 52 JM Davis (705_CR26) 2001; 62 H Ascher-Svanum (705_CR21) 2008; 34 DA Smelson (705_CR14) 2006; 26 CU Correll (705_CR22) 2003; 160 RE Drake (705_CR42) 1985; 142 MR Dossenbach (705_CR3) 2001; 62 HC Margolese (705_CR44) 2001; 101 PJ Weiden (705_CR8) 2003; 64 S Kapur (705_CR46) 2000; 321 SR Kay (705_CR25) 1987; 13 TR Barnes (705_CR30) 1989; 154 PJ Weiden (705_CR9) 2006; 20 DL Leslie (705_CR34) 2002; 159 S Hamer (705_CR1) 2007; 50 S Leucht (705_CR24) 2007; 68 JE Ware Jr (705_CR28) 1992; 30 SL Tunis (705_CR17) 2006; 9 H Liu-Seifert (705_CR11) 2005; 3 R Miller (705_CR51) 2009; 113 H Ascher-Svanum (705_CR47) 2005; 19 JA Lieberman (705_CR2) 2005; 353 GM Simpson (705_CR31) 1970; 212 S Almond (705_CR33) 2004; 184 AF Lehman (705_CR27) 1988; 11 SL Tunis (705_CR18) 2007; 23 SR Tunis (705_CR16) 2003; 290 H Ascher-Svanum (705_CR36) 2006; 67 P Czobor (705_CR49) 2002; 22 S Leucht (705_CR23) 2005; 57 S Park (705_CR5) 2005; 187 S Weinmann (705_CR13) 2004; 65 PJ Weiden (705_CR10) 2007; 68 BJ Kinon (705_CR40) 2008; 28 L Hansen (705_CR43) 2001; 16 DE Faries (705_CR15) 2009; 9 J Rabinowitz (705_CR41) 2008; 34 16649833 - J Clin Psychiatry. 2006 Mar;67(3):453-60 12006893 - J Clin Psychopharmacol. 2002 Jun;22(3):244-51 14506122 - JAMA. 2003 Sep 24;290(12):1624-32 19481424 - Schizophr Res. 2009 Sep;113(2-3):138-44 15632800 - J Behav Health Serv Res. 2005 Jan-Mar;32(1):85-94 16585434 - Am J Psychiatry. 2006 Apr;163(4):600-10 17110828 - J Clin Psychopharmacol. 2006 Dec;26(6):666-7 16375765 - BMC Med. 2005;3:21 15953491 - Biol Psychiatry. 2005 Jun 15;57(12):1543-9 11099266 - BMJ. 2000 Dec 2;321(7273):1360-1 7916523 - Acta Psychiatr Scand Suppl. 1994;382:11-5 2574607 - Br J Psychiatry. 1989 May;154:672-6 1593914 - Med Care. 1992 Jun;30(6):473-83 12413638 - Schizophr Res. 2003 Jan 1;59(1):19-27 18794651 - J Clin Psychopharmacol. 2008 Oct;28(5):544-9 16585435 - Am J Psychiatry. 2006 Apr;163(4):611-22 938196 - Arch Gen Psychiatry. 1976 Jun;33(6):766-71 16172203 - N Engl J Med. 2005 Sep 22;353(12):1209-23 16280344 - J Psychopharmacol. 2005 Nov;19(6 Suppl):110-7 16204323 - J Psychopharmacol. 2006 Jan;20(1):104-18 12404546 - Hum Psychopharmacol. 2001 Oct;16(7):495-505 14662555 - Arch Gen Psychiatry. 2003 Dec;60(12):1228-35 11816864 - J Clin Psychiatry. 2001 Oct;62(10):757-71 15056580 - Br J Psychiatry. 2004 Apr;184:346-51 3616518 - Schizophr Bull. 1987;13(2):261-76 16504026 - BMC Psychiatry. 2006;6:8 18156640 - Schizophr Bull. 2008 Nov;34(6):1163-71 15323596 - J Clin Psychiatry. 2004 Aug;65(8):1099-105 12202274 - Am J Psychiatry. 2002 Sep;159(9):1534-40 12365874 - Arch Gen Psychiatry. 2002 Oct;59(10):877-83 17539698 - J Clin Psychiatry. 2007;68 Suppl 4:34-9 7481573 - Schizophr Bull. 1995;21(3):419-29 11376229 - Psychiatr Serv. 2001 Jun;52(6):805-11 16889456 - J Clin Psychiatry. 2006 Jul;67(7):1114-23 17257471 - Curr Med Res Opin. 2007 Jan;23(1):97-104 19725969 - BMC Psychiatry. 2009;9:54 4917967 - Acta Psychiatr Scand Suppl. 1970;212:11-9 16055824 - Br J Psychiatry. 2005 Aug;187:137-42 12755663 - J Clin Psychiatry. 2003 May;64(5):580-8 3976927 - Am J Psychiatry. 1985 Apr;142(4):499-501 17329466 - Am J Psychiatry. 2007 Mar;164(3):415-27 14594760 - Am J Psychiatry. 2003 Nov;160(11):2063-5 14557530 - Psychiatr Serv. 2003 Oct;54(10):1407-9 17388703 - J Clin Psychiatry. 2007 Mar;68(3):352-60 11232749 - J Clin Psychiatry. 2001;62 Suppl 2:28-34 18019047 - Br J Psychiatry Suppl. 2007 Aug;50:s64-70 18212325 - Schizophr Bull. 2008 Mar;34(2):286-91 16626411 - Value Health. 2006 Mar-Apr;9(2):77-89 |
References_xml | – volume: 34 start-page: 1163 issue: 6 year: 2008 ident: 705_CR21 publication-title: Schizophr Bull doi: 10.1093/schbul/sbm134 – volume: 59 start-page: 19 issue: 1 year: 2003 ident: 705_CR50 publication-title: Schizophr Res doi: 10.1016/S0920-9964(01)00326-7 – volume: 9 start-page: 77 issue: 2 year: 2006 ident: 705_CR17 publication-title: Value Health doi: 10.1111/j.1524-4733.2006.00083.x – volume: 101 start-page: 128 year: 2001 ident: 705_CR44 publication-title: Acta Psychiatr Belg – volume: 160 start-page: 2063 issue: 11 year: 2003 ident: 705_CR22 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.160.11.2063 – volume: 159 start-page: 1534 issue: 9 year: 2002 ident: 705_CR34 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.159.9.1534 – volume: 68 start-page: 34 issue: Suppl 4 year: 2007 ident: 705_CR10 publication-title: J Clin Psychiatry – volume: 163 start-page: 611 issue: 4 year: 2006 ident: 705_CR6 publication-title: Am J Psychiatry doi: 10.1176/ajp.2006.163.4.611 – volume: 68 start-page: 352 issue: 3 year: 2007 ident: 705_CR24 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v68n0301 – volume: 154 start-page: 672 year: 1989 ident: 705_CR30 publication-title: Br J Psychiatry doi: 10.1192/bjp.154.5.672 – volume: 13 start-page: 261 issue: 2 year: 1987 ident: 705_CR25 publication-title: Schizophr Bull doi: 10.1093/schbul/13.2.261 – volume: 6 start-page: 8 year: 2006 ident: 705_CR48 publication-title: BMC Psychiatry doi: 10.1186/1471-244X-6-8 – volume: 184 start-page: 346 year: 2004 ident: 705_CR33 publication-title: Br J Psychiatry doi: 10.1192/bjp.184.4.346 – volume: 52 start-page: 805 issue: 6 year: 2001 ident: 705_CR38 publication-title: Psychiatr Serv doi: 10.1176/appi.ps.52.6.805 – volume: 23 start-page: 97 issue: 1 year: 2007 ident: 705_CR18 publication-title: Curr Med Res Opin doi: 10.1185/030079907X162665 – volume: 382 start-page: 11 year: 1994 ident: 705_CR45 publication-title: Acta Psychiatr Scand – volume: 50 start-page: s64 year: 2007 ident: 705_CR1 publication-title: Br J Psychiatry Suppl doi: 10.1192/bjp.191.50.s64 – volume: 21 start-page: 419 issue: 3 year: 1995 ident: 705_CR35 publication-title: Schizophr Bull doi: 10.1093/schbul/21.3.419 – volume: 142 start-page: 499 issue: 4 year: 1985 ident: 705_CR42 publication-title: Am J Psychiatry doi: 10.1176/ajp.142.4.499 – volume: 59 start-page: 877 issue: 10 year: 2002 ident: 705_CR32 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.59.10.877 – volume: 9 start-page: 54 year: 2009 ident: 705_CR15 publication-title: BMC Psychiatry doi: 10.1186/1471-244X-9-54 – volume: 290 start-page: 1624 issue: 12 year: 2003 ident: 705_CR16 publication-title: J Am Med Assoc doi: 10.1001/jama.290.12.1624 – volume: 19 start-page: 110 issue: 6 Suppl year: 2005 ident: 705_CR47 publication-title: J Psychopharmacol doi: 10.1177/0269881105058978 – volume: 64 start-page: 580 issue: 5 year: 2003 ident: 705_CR8 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v64n0514 – volume: 353 start-page: 1209 issue: 12 year: 2005 ident: 705_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa051688 – volume: 3 start-page: 21 year: 2005 ident: 705_CR11 publication-title: BMC Med doi: 10.1186/1741-7015-3-21 – volume: 26 start-page: 666 issue: 6 year: 2006 ident: 705_CR14 publication-title: J Clin Psychopharmacol doi: 10.1097/01.jcp.0000245562.99036.92 – volume: 65 start-page: 1099 issue: 8 year: 2004 ident: 705_CR13 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v65n0812 – volume: 33 start-page: 766 issue: 6 year: 1976 ident: 705_CR29 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1976.01770060086012 – volume: 34 start-page: 286 issue: 2 year: 2008 ident: 705_CR41 publication-title: Schizophr Bull doi: 10.1093/schbul/sbm161 – volume: 212 start-page: 11 year: 1970 ident: 705_CR31 publication-title: Acta Psychiatr Scand Suppl doi: 10.1111/j.1600-0447.1970.tb02066.x – volume: 67 start-page: 453 issue: 3 year: 2006 ident: 705_CR36 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v67n0317 – volume: 62 start-page: 28 issue: Suppl 2 year: 2001 ident: 705_CR3 publication-title: J Clin Psychiatry – volume: 54 start-page: 1407 issue: 10 year: 2003 ident: 705_CR37 publication-title: Psychiatr Serv doi: 10.1176/appi.ps.54.10.1407 – volume: 164 start-page: 415 issue: 3 year: 2007 ident: 705_CR7 publication-title: Am J Psychiatry doi: 10.1176/ajp.2007.164.3.415 – volume: 57 start-page: 1543 issue: 12 year: 2005 ident: 705_CR23 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2005.02.023 – volume: 28 start-page: 544 issue: 5 year: 2008 ident: 705_CR40 publication-title: J Clin Psychopharmacol doi: 10.1097/JCP.0b013e318185e74a – volume: 11 start-page: 51 issue: 4 year: 1988 ident: 705_CR27 publication-title: Eval Program Plann doi: 10.1016/0149-7189(88)90033-X – volume: 30 start-page: 473 issue: 6 year: 1992 ident: 705_CR28 publication-title: Med Care doi: 10.1097/00005650-199206000-00002 – volume: 163 start-page: 600 issue: 4 year: 2006 ident: 705_CR4 publication-title: Am J Psychiatry doi: 10.1176/ajp.2006.163.4.600 – volume: 67 start-page: 1114 issue: 7 year: 2006 ident: 705_CR39 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v67n0715 – volume: 16 start-page: 495 issue: 7 year: 2001 ident: 705_CR43 publication-title: Hum Psychopharmacol doi: 10.1002/hup.325 – volume: 22 start-page: 244 issue: 3 year: 2002 ident: 705_CR49 publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-200206000-00003 – volume: 10 start-page: 799 year: 1962 ident: 705_CR19 publication-title: Psychol Rep doi: 10.2466/pr0.1962.10.3.799 – volume: 32 start-page: 85 issue: 1 year: 2005 ident: 705_CR12 publication-title: J Behav Health Serv Res doi: 10.1007/BF02287330 – volume: 321 start-page: 1360 issue: 7273 year: 2000 ident: 705_CR46 publication-title: BMJ doi: 10.1136/bmj.321.7273.1360 – volume: 62 start-page: 757 issue: 10 year: 2001 ident: 705_CR26 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v62n1003 – volume: 187 start-page: 137 year: 2005 ident: 705_CR5 publication-title: Br J Psychiatry doi: 10.1192/bjp.187.2.137 – volume: 60 start-page: 1228 issue: 12 year: 2003 ident: 705_CR20 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.60.12.1228 – volume: 20 start-page: 104 issue: 1 year: 2006 ident: 705_CR9 publication-title: J Psychopharmacol doi: 10.1177/0269881105056668 – volume: 113 start-page: 138 issue: 2-3 year: 2009 ident: 705_CR51 publication-title: Schizophr Res doi: 10.1016/j.schres.2009.04.018 – reference: 16504026 - BMC Psychiatry. 2006;6:8 – reference: 16280344 - J Psychopharmacol. 2005 Nov;19(6 Suppl):110-7 – reference: 14662555 - Arch Gen Psychiatry. 2003 Dec;60(12):1228-35 – reference: 12202274 - Am J Psychiatry. 2002 Sep;159(9):1534-40 – reference: 17388703 - J Clin Psychiatry. 2007 Mar;68(3):352-60 – reference: 18212325 - Schizophr Bull. 2008 Mar;34(2):286-91 – reference: 3976927 - Am J Psychiatry. 1985 Apr;142(4):499-501 – reference: 938196 - Arch Gen Psychiatry. 1976 Jun;33(6):766-71 – reference: 15323596 - J Clin Psychiatry. 2004 Aug;65(8):1099-105 – reference: 7481573 - Schizophr Bull. 1995;21(3):419-29 – reference: 12755663 - J Clin Psychiatry. 2003 May;64(5):580-8 – reference: 15056580 - Br J Psychiatry. 2004 Apr;184:346-51 – reference: 17257471 - Curr Med Res Opin. 2007 Jan;23(1):97-104 – reference: 19481424 - Schizophr Res. 2009 Sep;113(2-3):138-44 – reference: 11376229 - Psychiatr Serv. 2001 Jun;52(6):805-11 – reference: 12006893 - J Clin Psychopharmacol. 2002 Jun;22(3):244-51 – reference: 14594760 - Am J Psychiatry. 2003 Nov;160(11):2063-5 – reference: 11099266 - BMJ. 2000 Dec 2;321(7273):1360-1 – reference: 17110828 - J Clin Psychopharmacol. 2006 Dec;26(6):666-7 – reference: 1593914 - Med Care. 1992 Jun;30(6):473-83 – reference: 4917967 - Acta Psychiatr Scand Suppl. 1970;212:11-9 – reference: 16172203 - N Engl J Med. 2005 Sep 22;353(12):1209-23 – reference: 12404546 - Hum Psychopharmacol. 2001 Oct;16(7):495-505 – reference: 16055824 - Br J Psychiatry. 2005 Aug;187:137-42 – reference: 3616518 - Schizophr Bull. 1987;13(2):261-76 – reference: 17539698 - J Clin Psychiatry. 2007;68 Suppl 4:34-9 – reference: 16204323 - J Psychopharmacol. 2006 Jan;20(1):104-18 – reference: 16649833 - J Clin Psychiatry. 2006 Mar;67(3):453-60 – reference: 12365874 - Arch Gen Psychiatry. 2002 Oct;59(10):877-83 – reference: 14557530 - Psychiatr Serv. 2003 Oct;54(10):1407-9 – reference: 14506122 - JAMA. 2003 Sep 24;290(12):1624-32 – reference: 18156640 - Schizophr Bull. 2008 Nov;34(6):1163-71 – reference: 16626411 - Value Health. 2006 Mar-Apr;9(2):77-89 – reference: 18019047 - Br J Psychiatry Suppl. 2007 Aug;50:s64-70 – reference: 15953491 - Biol Psychiatry. 2005 Jun 15;57(12):1543-9 – reference: 12413638 - Schizophr Res. 2003 Jan 1;59(1):19-27 – reference: 19725969 - BMC Psychiatry. 2009;9:54 – reference: 15632800 - J Behav Health Serv Res. 2005 Jan-Mar;32(1):85-94 – reference: 11816864 - J Clin Psychiatry. 2001 Oct;62(10):757-71 – reference: 18794651 - J Clin Psychopharmacol. 2008 Oct;28(5):544-9 – reference: 11232749 - J Clin Psychiatry. 2001;62 Suppl 2:28-34 – reference: 2574607 - Br J Psychiatry. 1989 May;154:672-6 – reference: 16375765 - BMC Med. 2005;3:21 – reference: 7916523 - Acta Psychiatr Scand Suppl. 1994;382:11-5 – reference: 16585435 - Am J Psychiatry. 2006 Apr;163(4):611-22 – reference: 16889456 - J Clin Psychiatry. 2006 Jul;67(7):1114-23 – reference: 17329466 - Am J Psychiatry. 2007 Mar;164(3):415-27 – reference: 16585434 - Am J Psychiatry. 2006 Apr;163(4):600-10 |
SSID | ssj0017851 |
Score | 2.1108406 |
Snippet | To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in the... Background To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents in... Abstract Background: To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic... BACKGROUND: To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic agents... Abstract Background To identify patient characteristics and early changes in patients' clinical status that best predict subsequent switching of antipsychotic... |
SourceID | doaj pubmedcentral biomedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 75 |
SubjectTerms | Ambulatory Care Antipsychotic Agents - administration & dosage Antipsychotic Agents - therapeutic use Antipsychotic drugs Care and treatment Clinical medicine Cost control Drug Administration Schedule Female Follow-Up Studies Health aspects Humans Male Middle Aged Multicenter Studies as Topic - statistics & numerical data Patient outcomes Probability Proportional Hazards Models Psychiatric Status Rating Scales - statistics & numerical data Psychiatry Psychotropic drugs Randomized Controlled Trials as Topic - statistics & numerical data Schizophrenia Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenic Psychology Severity of Illness Index Survival Analysis Treatment Outcome |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA_Sg3gR6-fYKjkIehk7k0wyCT1VsRShImhhbyHJJDhQZqW7xX_f9zLZYUMpXrwtk4SZvLzPfS-_R8g7GcAJFnaorZQDphljraMbas0wrTSw1gm8KHz5TV5cdV9XYrXX6gtrwmZ44JlwJzbIGJVsePSqU9JZCHu0dQiUpoc-JiRQsHm7YCrnD7DlfLpX1Lc1GLBVBvVplTxZnqEGwvLC4qL7dWGfEoz_XWW9Z63KSso903T-hDzOPiU9m_dySB6E6Sl5eJmz5s_Ij-83-Bv76tB1pJs_4zZVUFKg6pivYY2epjT7_AceHScKniFdytDTuv36vOfk6vzLz88XdW6mUDtwOra19D0PEuQ7iDiAUY9taPgAmrqzEfsHySADd5b3ESTYO676INuhaQJWVHPf8hfkYFpP4RWhrgGnT0jLHAQjTCsreSsb3wnseGODq8hpQVLzewbOMAhlXY6AVBk8EIMHYiAg6UVFPu4OwPiMU47tMq5NileUvLvgw7Jg96Z7p37CEy0-KD0AjjOZ48y_OK4i75EfDGoA-DBv80UGIA5iaZkzhj6nkppV5LiYCZLri-GjHUeZrDk2RqPT1XcCXkOXUVyIxXBTWN9uYB_YIZqL5v4pGhxjjb5rRV7OHLrsGaSFoRquSF_wbkGUcmQafyXgcaYRTq59_T-oeEQezYUYumbqmBxsb27DG_Dvtu5tEuW_vDxNcQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFD_oBPFF_LbblDwI-lLXNm3a4INMcQxhIujgvoUkTVxhtPPeO_z3d05ubrlhzLdLk3DTnO-ek98BeCccOsGN7nMtRE9pRp9Lb_pcVpRW6qvSNHRR-OyHOD2vvy-aRazNWcWyyq1ODIq6nyx9Iz-SZIzauqk_X_3NqWkUJVdjB4378ICQy4ip28Ucb4W-8xHNp-zEUYl6OEdrtiDVQ3WFyQ33y8QwBfz-21p6x0ylJZQ7NunkCTyOziQ73lD_Kdxz4zN4eBbT5c_h188l_aaGOmzybPVvWIfSSYbHOcT7V4NlIb---XLHhpGhS8jm-vOwbrcw7wWcn3z7_fU0j10UcoPexjoXtuVOoGC7xvdozX3pCt6jiq61p8ZBwgnHjeatR9G1hnetE2VfFI5Kqbkt-UvYG6fRvQZmCvT2GqErg1FIJTsteCkKWzfU6kY7k8Gn5EjV1QYxQxGGdTqCpFVEEEUEURiJtE0GH7cEUDYClFOfjEsVApVO3F7wYV6w_ac7p34hiiYbCg-m5R8VZVRpJ7zvRMG97epOGI0RttSGMPlk3_o6g_fED4pEHzdmdbzBgIdDIFrquCJnsxOyyuAwmYkia5Phgy1HqagyVmpm8AzYPEoLqQpudNP1Ct-DWkPzprh7ikSPWJLTmsGrDYfO71wVKICofzNoE95NDiUdGYeLgDheScKRK_f_u-8DeLQprZB51R3C3np57d6gx7Y2b4Nc3gBW4EIu priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbB2Mvpft22w09DLYXd7ZlSRallG6slEHGYAvkTUi21BmCsyUp2_773cl2GtH2ZW8h0mH5dKf7ne90R8gb4QAEc9OkRogGw4w-Vd42qSowrNQUueV4UXjyRVxMy88zPrtuBzQwcHWra4f9pKbL-dGfX39PQeFPgsJX4n0OB2wKZmqGZ4rk98kDMEsS2xlMyuuQAnahH2r73EKERYEzWGCOOV3R1fd5ZLFCYf-bx_eW_YpzK7eM1fke2R1QJj3rxeIxuee6J-ThZIijPyXfvi7xN3baoQtPV7_bdcippMDndriY1dY0BN77T3q07ShgRbpJTA902xl7z8j0_NP3jxfp0F4htQBD1qmoJXMCNN5x34CZ97nLWANnd2k8dhQSTjhmDZMedLq2rJJO5E2WOcyxZnXOnpOdbtG5l4TaDGAgF6aw4J4UqjKC5SKrS449cIyzCTmOWKp_9qU0NBa3jkdAzzTujca90eCiSJ6Qo3EDdD1ULscGGnMdPJhK3CR4tyEYn3Tn1A-4o9GCwh-L5aUelFcbJ7yvRMZ8XZWVsAZcb2UsFutTjfRlQt6iPGiUUlhYbYarDcAcrK6lzwpEoZVQRUIOo5mgy3U0fDBKlB5VQSuEYbLk8Bi6GUVCTI_r3OJqBe-BPaMZz-6eogAqK0SzCXnRS-jmnUfBT4iMZDdiSjzStT9CKfJCYYG5fP-_KQ_Ioz4fQ6VFdUh21ssr9wpg3tq-Dur7D4KiUlM priority: 102 providerName: Scholars Portal |
Title | Predictors of switching antipsychotic medications in the treatment of schizophrenia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20920179 https://www.proquest.com/docview/902187454 https://www.proquest.com/docview/758833350 https://www.proquest.com/docview/954591251 http://dx.doi.org/10.1186/1471-244X-10-75 https://pubmed.ncbi.nlm.nih.gov/PMC2955631 https://doaj.org/article/ae6ff8603fc8486ba9789ab96099d7f4 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED_WFsZexr7ntgt-GGwv3mzZki321IyWMkgp2wphL0KyJWoozmhS9u_3TlayqF2f9hJCJMW2Tnf3O98XwHthEQRz3WVaiI7cjC6TznSZZORW6lhhOCUKz87E6UX1bc7nf4tF3_HgF434XKD4zFAJzUli1HwH9liF9hwZ5tNfG4cB9Zj3iURhcqji848_uJPZfhUpJF-3_7503lJPcejkli46eQZPA4hMj0aqP4dHdngBj2fBTf4Sfpxf03dqpJMuXLr80698yGSK29iHvKu-Tb1ffXxjl_ZDilAw3cSd-3XbAXmv4OLk-OfX0yx0T8gMooxVJtq6tAIZ2nLXoRZ3hc3LDkVzpR01DBJW2NLosnbIsq0pm9qKostzSyHUZVuUr2F3WAz2LaQmR5THhWYGrQ8mGy3KQuRtxanFjbYmgS_RlqrfY6UMRbWr4xFkI0UEUUQQhRZIzRP4tCaAakNhcuqPcaW8gdKI-ws-bhasr_Tg1ClRNLoh_wOeMBV4U2krnGtEXrq2qRphNFrWUhuqxSe72lUJfKDzoIjl8cZaHTIXcHOoeJY6YgQyGyFZAofRTGTVNho-WJ8oFUTFUklCWXXF8TLpZpQWUvTbYBc3S3wOagld8vzhKRKRsCSwmsCb8YRunpnlyHgodxOoo7MbbUo8MvSXvtI4k1Q_rtj_L_oewJMx5EJmrDmE3dX1jX2HSG5lJrBTz-sJ7E2Pz86_T_z7EPycVc3Ec_ctzw1J2g |
linkProvider | BioMedCentral |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgEXxJvQAj6A4BKaOIkTCyFUHtWWdiskWmlvrp3YdKUq2-5uVfGj-I_M5KW1qnLrbbW2dx3P-JuZzAvgjbCoBGe6CrUQFbkZXSidqULJya1U8dhklCg8PhCjo_THJJuswd8-F4bCKntMbIC6mpX0jnxLkjDK0yz9fHYeUtMocq72HTRartizfy7RYlt82v2G5H3L-c73w6-jsGsqEBoUvstQlHliBfK5zVyFws3FNkoqRKxUO-qjI6ywidFJ7pCTS5MUuRVxFUWWIouTMk7wd2_BbZS7Edl6-WSw75o-9131oLgQWzHifojSc0JQR3GMXkb9qScIm34BV6XCilj0QzZXZODOA7jfKa9su-W2h7Bm60dwZ9y55x_Dr59z-kwNfNjMscXldNmEajIk37TL95qWrPHnt28K2bRmqIKyId69WbcaCPgEjm7kgJ_Cej2r7XNgJkLtMhOaG7R6uCy0SGIRlWlGrXW0NQF89I5UnbUVOhTVzPZHkJUUEUQRQRRaPnkWwIeeAKrsCqJTX45T1RhGhbi64P2woP-na6d-IYp6G2q-mM1_qw4TlLbCuUJEiSuLtBBGo0UvtaEagLLKXRrAO-IHRVCDGyt1lzGBh0NFu9Q2J-W2EJIHsOnNRIgoveGNnqNUB1ELNVyoANgwSgsp6q62s4sFPge1ok6y6PopEjVwSUpyAM9aDh2emUd44RHvA8g93vUOxR-ppydNhXMuqW5d_OK_-34Nd0eH4321v3uwtwH32rAOGfJiE9aX8wv7ErXFpXnV3FEGxzcNCv8A59WAfQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcEG9CC_gAgkvaxEmcWIhDS1m1lFYVUGnFxdiJDRFLttrdquKn8e-YyYsNpSfUW7S2N7Zn_M1MPA-AZ8KiEpzowtdCFHTN6HzpTOFLTtdKBQ9NQoHCh0di7yR-N07GK_Cri4UxP_I_br6byyHokxq38SH_vnVauOa4Z2IrRHj1UUiNCVHSzr_ywP48R-tt_np_F0n9nPPR209v9vy2wIBvUBAvfJGnkRXI8zZxBQo6F9ogKhC9Yu2opo6wwkZGR6lDrs5NlKVWhEUQWPIyjvIwwv-9BtdxsSkVT_iw87m_wKCa93VgUzu5NqvQPyb8V6T9ZCAg6zoCF6XFkrgcunIuycbRLbjZKrVsu-HC27Biqzuwdthe29-Fj8czeqbCPmzq2Py8XNQunAzJWrZxYGXO6nv-5gsiKyuGqinr_eDrccsOgvfg5Eo2-z6sVtPKPgRmAtQ6E6G5QWuIy0yLKBRBHidUckdb48GrwZaq0yZzh6Jc2sMW5ClFBFFEEIUWUZp4sNkRQOVtonSq1zFRtcGUiYsDXvYDujdd2nWHKDqYUP3DdPZVtVihtBXOZSKIXJ7FmTAaLX2pDeUGlEXqYg9eED8ogiA6D7qNpMDNoWReapuT0psJyT3YGPRE6MgHzesdR6kWuuZKktaXxgm-hvWtNJC88So7PZvjOqhEdZQEl3eRqJlLUp49eNBwaL9mHiAQoBzwIB3w7mBThi1V-a3OfM4l5bMLH_0XfZ_C2vHuSL3fPzpYhxuNN4j0ebYBq4vZmX2MSubCPKmPM4MvV40fvwHHgJCh |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictors+of+switching+antipsychotic+medications+in+the+treatment+of+schizophrenia&rft.jtitle=BMC+psychiatry&rft.au=Nyhuis%2C+Allen+W&rft.au=Faries%2C+Douglas+E&rft.au=Ascher-Svanum%2C+Haya&rft.au=Stauffer%2C+Virginia+L&rft.date=2010-09-28&rft.pub=BioMed+Central&rft.eissn=1471-244X&rft.volume=10&rft.spage=75&rft.epage=75&rft_id=info:doi/10.1186%2F1471-244X-10-75&rft_id=info%3Apmid%2F20920179&rft.externalDocID=PMC2955631 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-244X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-244X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-244X&client=summon |